Saturna Capital Corp Buys 1,618 Shares of Edwards Lifesciences Co. (NYSE:EW)

Saturna Capital Corp increased its stake in Edwards Lifesciences Co. (NYSE:EW) by 7.1% during the third quarter, Holdings Channel reports. The firm owned 24,534 shares of the medical research company’s stock after acquiring an additional 1,618 shares during the period. Saturna Capital Corp’s holdings in Edwards Lifesciences were worth $1,619,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of EW. Crewe Advisors LLC bought a new position in Edwards Lifesciences in the first quarter valued at about $28,000. First Community Trust NA bought a new position in Edwards Lifesciences in the second quarter valued at about $29,000. Webster Bank N. A. bought a new position in Edwards Lifesciences in the second quarter valued at about $39,000. Peoples Bank KS bought a new position in Edwards Lifesciences in the third quarter valued at about $40,000. Finally, Versant Capital Management Inc grew its holdings in shares of Edwards Lifesciences by 206.3% during the second quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock worth $45,000 after purchasing an additional 326 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Insider Activity

In other news, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares in the company, valued at $13,084,848.66. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares in the company, valued at $13,084,848.66. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the sale, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 36,250 shares of company stock worth $2,416,588 over the last quarter. 1.27% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. TD Cowen cut Edwards Lifesciences from a “buy” rating to a “hold” rating and reduced their price target for the stock from $100.00 to $70.00 in a report on Thursday, July 25th. Canaccord Genuity Group reduced their price target on Edwards Lifesciences from $66.00 to $63.00 and set a “hold” rating on the stock in a report on Friday, October 25th. Evercore ISI reduced their price target on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a report on Tuesday, October 1st. Oppenheimer restated an “outperform” rating and set a $90.00 price target on shares of Edwards Lifesciences in a report on Thursday, September 12th. Finally, The Goldman Sachs Group reduced their price target on Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating on the stock in a report on Friday, July 26th. Seventeen research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences currently has an average rating of “Hold” and an average price target of $75.67.

Edwards Lifesciences Price Performance

Shares of EW opened at $65.90 on Wednesday. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The business’s 50 day moving average price is $67.47 and its two-hundred day moving average price is $76.51. The firm has a market cap of $38.87 billion, a PE ratio of 9.50, a price-to-earnings-growth ratio of 3.75 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.67. The firm had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company’s revenue was up 8.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.59 earnings per share. On average, equities analysts anticipate that Edwards Lifesciences Co. will post 2.57 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.